Abstract
The pathophysiology, diagnosis and treatment of female sexual interest in pre- and post-menopausal women present a complex arena for patients and physicians to navigate. Flibanserin was the first pharmacologic treatment, approved by the United States Food and Drug Administration in August 2015, for hypoactive sexual desire disorder (HSDD) in premenopausal women. Side effects, contraindications and lack of approval in postmenopausal women are all limitations, as are issues surrounding patient and physician knowledge and access. Testosterone, buspirone, sildenafil, bupropion, bremelanotide, as well as herbal medications (Herbal vX or Tribulus terrestris) have demonstrated some clinical benefit in women with sexual dysfunction disorders however, trials have significant design, dosing or generalizability limitations. Nonpharmaceutical cognitive behavioral therapy, mindfulness meditation, pelvic floor therapy, and clitoral stimulators are also interventions women may pursue. This manuscript will explore the clinical data regarding these therapeutic modalities so as to bring attention to this issue of female HSDD, to offer an overview of current research, and to incite providers to initiate discussion among themselves and their patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 16-25 |
| Number of pages | 10 |
| Journal | Therapeutic Advances in Chronic Disease |
| Volume | 8 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2017 |
Fingerprint
Keywords
- female sexual interest and arousal disorders
- flibanserin
- hypoactive sexual desire disorder
- libido
- little pink pill
- sexual dysfunction
ASJC Scopus subject areas
- Medicine (miscellaneous)
Cite this
Flibanserin for hypoactive sexual desire disorder : place in therapy. / Gelman, Faina; Atrio, Jessica M.
In: Therapeutic Advances in Chronic Disease, Vol. 8, No. 1, 2017, p. 16-25.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Flibanserin for hypoactive sexual desire disorder
T2 - place in therapy
AU - Gelman, Faina
AU - Atrio, Jessica M.
PY - 2017
Y1 - 2017
N2 - The pathophysiology, diagnosis and treatment of female sexual interest in pre- and post-menopausal women present a complex arena for patients and physicians to navigate. Flibanserin was the first pharmacologic treatment, approved by the United States Food and Drug Administration in August 2015, for hypoactive sexual desire disorder (HSDD) in premenopausal women. Side effects, contraindications and lack of approval in postmenopausal women are all limitations, as are issues surrounding patient and physician knowledge and access. Testosterone, buspirone, sildenafil, bupropion, bremelanotide, as well as herbal medications (Herbal vX or Tribulus terrestris) have demonstrated some clinical benefit in women with sexual dysfunction disorders however, trials have significant design, dosing or generalizability limitations. Nonpharmaceutical cognitive behavioral therapy, mindfulness meditation, pelvic floor therapy, and clitoral stimulators are also interventions women may pursue. This manuscript will explore the clinical data regarding these therapeutic modalities so as to bring attention to this issue of female HSDD, to offer an overview of current research, and to incite providers to initiate discussion among themselves and their patients.
AB - The pathophysiology, diagnosis and treatment of female sexual interest in pre- and post-menopausal women present a complex arena for patients and physicians to navigate. Flibanserin was the first pharmacologic treatment, approved by the United States Food and Drug Administration in August 2015, for hypoactive sexual desire disorder (HSDD) in premenopausal women. Side effects, contraindications and lack of approval in postmenopausal women are all limitations, as are issues surrounding patient and physician knowledge and access. Testosterone, buspirone, sildenafil, bupropion, bremelanotide, as well as herbal medications (Herbal vX or Tribulus terrestris) have demonstrated some clinical benefit in women with sexual dysfunction disorders however, trials have significant design, dosing or generalizability limitations. Nonpharmaceutical cognitive behavioral therapy, mindfulness meditation, pelvic floor therapy, and clitoral stimulators are also interventions women may pursue. This manuscript will explore the clinical data regarding these therapeutic modalities so as to bring attention to this issue of female HSDD, to offer an overview of current research, and to incite providers to initiate discussion among themselves and their patients.
KW - female sexual interest and arousal disorders
KW - flibanserin
KW - hypoactive sexual desire disorder
KW - libido
KW - little pink pill
KW - sexual dysfunction
UR - http://www.scopus.com/inward/record.url?scp=85011580062&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011580062&partnerID=8YFLogxK
U2 - 10.1177/2040622316679933
DO - 10.1177/2040622316679933
M3 - Review article
AN - SCOPUS:85011580062
VL - 8
SP - 16
EP - 25
JO - Therapeutic Advances in Chronic Disease
JF - Therapeutic Advances in Chronic Disease
SN - 2040-6223
IS - 1
ER -